Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
Identifieur interne : 003410 ( Main/Exploration ); précédent : 003409; suivant : 003411Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
Auteurs : Ursula Schmidt-Erfurth [Autriche] ; Gabriele E. Lang [Allemagne] ; Frank G. Holz [Allemagne] ; Reinier O. Schlingemann [Pays-Bas] ; Paolo Lanzetta [Italie] ; Pascale Massin [France] ; Ortrud Gerstner [Suisse] ; Abdelkader Si Bouazza [Suisse] ; Haige Shen [République populaire de Chine] ; Aaron Osborne [Suisse] ; Paul Mitchell [Australie]Source :
- Ophthalmology [ 1549-4713 ] ; 2014.
Descripteurs français
- KwdFr :
- Acuité visuelle (physiologie), Adulte d'âge moyen, Anticorps monoclonaux humanisés (effets indésirables), Anticorps monoclonaux humanisés (usage thérapeutique), Coagulation par laser, Diabète de type 1 (), Diabète de type 2 (), Enquêtes et questionnaires, Facteurs temps, Femelle, Humains, Inhibiteurs de l'angiogenèse (effets indésirables), Inhibiteurs de l'angiogenèse (usage thérapeutique), Injections intravitréennes, Mâle, Médecine individualisée, Oedème maculaire (physiopathologie), Oedème maculaire (traitement médicamenteux), Profil d'impact de la maladie, Ranibizumab, Reprise du traitement, Résultat thérapeutique, Rétine (anatomopathologie), Rétinopathie diabétique (physiopathologie), Rétinopathie diabétique (traitement médicamenteux).
- MESH :
- anatomopathologie : Rétine.
- effets indésirables : Anticorps monoclonaux humanisés, Inhibiteurs de l'angiogenèse.
- physiologie : Acuité visuelle.
- physiopathologie : Oedème maculaire, Rétinopathie diabétique.
- traitement médicamenteux : Oedème maculaire, Rétinopathie diabétique.
- usage thérapeutique : Anticorps monoclonaux humanisés, Inhibiteurs de l'angiogenèse.
- Adulte d'âge moyen, Coagulation par laser, Diabète de type 1, Diabète de type 2, Enquêtes et questionnaires, Facteurs temps, Femelle, Humains, Injections intravitréennes, Mâle, Médecine individualisée, Profil d'impact de la maladie, Ranibizumab, Reprise du traitement, Résultat thérapeutique.
English descriptors
- KwdEn :
- Angiogenesis Inhibitors (adverse effects), Angiogenesis Inhibitors (therapeutic use), Antibodies, Monoclonal, Humanized (adverse effects), Antibodies, Monoclonal, Humanized (therapeutic use), Diabetes Mellitus, Type 1 (complications), Diabetes Mellitus, Type 2 (complications), Diabetic Retinopathy (drug therapy), Diabetic Retinopathy (physiopathology), Female, Humans, Intravitreal Injections, Laser Coagulation, Macular Edema (drug therapy), Macular Edema (physiopathology), Male, Middle Aged, Precision Medicine, Ranibizumab, Retina (pathology), Retreatment, Sickness Impact Profile, Surveys and Questionnaires, Time Factors, Treatment Outcome, Visual Acuity (physiology).
- MESH :
- chemical , adverse effects : Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized.
- chemical , therapeutic use : Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized.
- complications : Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2.
- drug therapy : Diabetic Retinopathy, Macular Edema.
- pathology : Retina.
- physiology : Visual Acuity.
- physiopathology : Diabetic Retinopathy, Macular Edema.
- Female, Humans, Intravitreal Injections, Laser Coagulation, Male, Middle Aged, Precision Medicine, Ranibizumab, Retreatment, Sickness Impact Profile, Surveys and Questionnaires, Time Factors, Treatment Outcome.
Abstract
To evaluate long-term efficacy and safety profiles during 3 years of individualized ranibizumab treatment in patients with visual impairment due to diabetic macular edema (DME).
DOI: 10.1016/j.ophtha.2013.11.041
PubMed: 24491642
Affiliations:
- Allemagne, Australie, Autriche, France, Italie, Pays-Bas, République populaire de Chine, Suisse
- Bade-Wurtemberg, District de Cologne, District de Tübingen, Hollande-Septentrionale, Nouvelle-Galles du Sud, Rhénanie-du-Nord-Westphalie, Vienne (Autriche), Île-de-France
- Amsterdam, Bonn, Paris, Sydney, Ulm, Vienne (Autriche)
- Université de Sydney
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003789
- to stream PubMed, to step Curation: 003675
- to stream PubMed, to step Checkpoint: 003675
- to stream Ncbi, to step Merge: 001769
- to stream Ncbi, to step Curation: 001769
- to stream Ncbi, to step Checkpoint: 001769
- to stream Main, to step Merge: 003422
- to stream Main, to step Curation: 003410
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.</title><author><name sortKey="Schmidt Erfurth, Ursula" sort="Schmidt Erfurth, Ursula" uniqKey="Schmidt Erfurth U" first="Ursula" last="Schmidt-Erfurth">Ursula Schmidt-Erfurth</name><affiliation wicri:level="3"><nlm:affiliation>Department of Ophthalmology, Medical University Vienna, Vienna, Austria. Electronic address: ursula.schmidt-erfurth@meduniwien.ac.at.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Ophthalmology, Medical University Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Lang, Gabriele E" sort="Lang, Gabriele E" uniqKey="Lang G" first="Gabriele E" last="Lang">Gabriele E. Lang</name><affiliation wicri:level="3"><nlm:affiliation>Division of Medical Retina and Laser Surgery, Department of Ophthalmology, University Eye Hospital Ulm, Ulm, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Division of Medical Retina and Laser Surgery, Department of Ophthalmology, University Eye Hospital Ulm, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement></placeName></affiliation></author><author><name sortKey="Holz, Frank G" sort="Holz, Frank G" uniqKey="Holz F" first="Frank G" last="Holz">Frank G. Holz</name><affiliation wicri:level="3"><nlm:affiliation>Department of Ophthalmology, University of Bonn, Bonn, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Ophthalmology, University of Bonn, Bonn</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Bonn</settlement></placeName></affiliation></author><author><name sortKey="Schlingemann, Reinier O" sort="Schlingemann, Reinier O" uniqKey="Schlingemann R" first="Reinier O" last="Schlingemann">Reinier O. Schlingemann</name><affiliation wicri:level="3"><nlm:affiliation>Medical Retina Unit and Ocular Angiogenesis Group, Department of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands; Netherlands Institute for Neuroscience (NIN), Royal Academy of Sciences (KNAW), Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Medical Retina Unit and Ocular Angiogenesis Group, Department of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands; Netherlands Institute for Neuroscience (NIN), Royal Academy of Sciences (KNAW), Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Lanzetta, Paolo" sort="Lanzetta, Paolo" uniqKey="Lanzetta P" first="Paolo" last="Lanzetta">Paolo Lanzetta</name><affiliation wicri:level="1"><nlm:affiliation>Department of Ophthalmology, University of Udine, Udine, Italy; Istituto Europeo di Microchirurgia Oculare (IEMO), Udine, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Ophthalmology, University of Udine, Udine, Italy; Istituto Europeo di Microchirurgia Oculare (IEMO), Udine</wicri:regionArea><wicri:noRegion>Udine</wicri:noRegion></affiliation></author><author><name sortKey="Massin, Pascale" sort="Massin, Pascale" uniqKey="Massin P" first="Pascale" last="Massin">Pascale Massin</name><affiliation wicri:level="3"><nlm:affiliation>Assistance Publique des Hopitaux de Paris, Université Paris Diderot, Ophthalmology Department, Hopital Lariboisiere, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Assistance Publique des Hopitaux de Paris, Université Paris Diderot, Ophthalmology Department, Hopital Lariboisiere, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Gerstner, Ortrud" sort="Gerstner, Ortrud" uniqKey="Gerstner O" first="Ortrud" last="Gerstner">Ortrud Gerstner</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Bouazza, Abdelkader Si" sort="Bouazza, Abdelkader Si" uniqKey="Bouazza A" first="Abdelkader Si" last="Bouazza">Abdelkader Si Bouazza</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Shen, Haige" sort="Shen, Haige" uniqKey="Shen H" first="Haige" last="Shen">Haige Shen</name><affiliation wicri:level="1"><nlm:affiliation>Beijing Novartis Pharmaceuticals Co., Ltd., Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Beijing Novartis Pharmaceuticals Co., Ltd., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Osborne, Aaron" sort="Osborne, Aaron" uniqKey="Osborne A" first="Aaron" last="Osborne">Aaron Osborne</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name><affiliation wicri:level="4"><nlm:affiliation>Centre for Vision Research (Westmead Millennium Institute), University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Centre for Vision Research (Westmead Millennium Institute), University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24491642</idno><idno type="pmid">24491642</idno><idno type="doi">10.1016/j.ophtha.2013.11.041</idno><idno type="wicri:Area/PubMed/Corpus">003789</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003789</idno><idno type="wicri:Area/PubMed/Curation">003675</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003675</idno><idno type="wicri:Area/PubMed/Checkpoint">003675</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003675</idno><idno type="wicri:Area/Ncbi/Merge">001769</idno><idno type="wicri:Area/Ncbi/Curation">001769</idno><idno type="wicri:Area/Ncbi/Checkpoint">001769</idno><idno type="wicri:Area/Main/Merge">003422</idno><idno type="wicri:Area/Main/Curation">003410</idno><idno type="wicri:Area/Main/Exploration">003410</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.</title><author><name sortKey="Schmidt Erfurth, Ursula" sort="Schmidt Erfurth, Ursula" uniqKey="Schmidt Erfurth U" first="Ursula" last="Schmidt-Erfurth">Ursula Schmidt-Erfurth</name><affiliation wicri:level="3"><nlm:affiliation>Department of Ophthalmology, Medical University Vienna, Vienna, Austria. Electronic address: ursula.schmidt-erfurth@meduniwien.ac.at.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Ophthalmology, Medical University Vienna, Vienna</wicri:regionArea><placeName><settlement type="city">Vienne (Autriche)</settlement><region nuts="2" type="province">Vienne (Autriche)</region></placeName></affiliation></author><author><name sortKey="Lang, Gabriele E" sort="Lang, Gabriele E" uniqKey="Lang G" first="Gabriele E" last="Lang">Gabriele E. Lang</name><affiliation wicri:level="3"><nlm:affiliation>Division of Medical Retina and Laser Surgery, Department of Ophthalmology, University Eye Hospital Ulm, Ulm, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Division of Medical Retina and Laser Surgery, Department of Ophthalmology, University Eye Hospital Ulm, Ulm</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Tübingen</region><settlement type="city">Ulm</settlement></placeName></affiliation></author><author><name sortKey="Holz, Frank G" sort="Holz, Frank G" uniqKey="Holz F" first="Frank G" last="Holz">Frank G. Holz</name><affiliation wicri:level="3"><nlm:affiliation>Department of Ophthalmology, University of Bonn, Bonn, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Ophthalmology, University of Bonn, Bonn</wicri:regionArea><placeName><region type="land" nuts="1">Rhénanie-du-Nord-Westphalie</region><region type="district" nuts="2">District de Cologne</region><settlement type="city">Bonn</settlement></placeName></affiliation></author><author><name sortKey="Schlingemann, Reinier O" sort="Schlingemann, Reinier O" uniqKey="Schlingemann R" first="Reinier O" last="Schlingemann">Reinier O. Schlingemann</name><affiliation wicri:level="3"><nlm:affiliation>Medical Retina Unit and Ocular Angiogenesis Group, Department of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands; Netherlands Institute for Neuroscience (NIN), Royal Academy of Sciences (KNAW), Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Medical Retina Unit and Ocular Angiogenesis Group, Department of Ophthalmology, Academic Medical Center, Amsterdam, The Netherlands; Netherlands Institute for Neuroscience (NIN), Royal Academy of Sciences (KNAW), Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Lanzetta, Paolo" sort="Lanzetta, Paolo" uniqKey="Lanzetta P" first="Paolo" last="Lanzetta">Paolo Lanzetta</name><affiliation wicri:level="1"><nlm:affiliation>Department of Ophthalmology, University of Udine, Udine, Italy; Istituto Europeo di Microchirurgia Oculare (IEMO), Udine, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Ophthalmology, University of Udine, Udine, Italy; Istituto Europeo di Microchirurgia Oculare (IEMO), Udine</wicri:regionArea><wicri:noRegion>Udine</wicri:noRegion></affiliation></author><author><name sortKey="Massin, Pascale" sort="Massin, Pascale" uniqKey="Massin P" first="Pascale" last="Massin">Pascale Massin</name><affiliation wicri:level="3"><nlm:affiliation>Assistance Publique des Hopitaux de Paris, Université Paris Diderot, Ophthalmology Department, Hopital Lariboisiere, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Assistance Publique des Hopitaux de Paris, Université Paris Diderot, Ophthalmology Department, Hopital Lariboisiere, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Gerstner, Ortrud" sort="Gerstner, Ortrud" uniqKey="Gerstner O" first="Ortrud" last="Gerstner">Ortrud Gerstner</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Bouazza, Abdelkader Si" sort="Bouazza, Abdelkader Si" uniqKey="Bouazza A" first="Abdelkader Si" last="Bouazza">Abdelkader Si Bouazza</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Shen, Haige" sort="Shen, Haige" uniqKey="Shen H" first="Haige" last="Shen">Haige Shen</name><affiliation wicri:level="1"><nlm:affiliation>Beijing Novartis Pharmaceuticals Co., Ltd., Shanghai, China.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Beijing Novartis Pharmaceuticals Co., Ltd., Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Osborne, Aaron" sort="Osborne, Aaron" uniqKey="Osborne A" first="Aaron" last="Osborne">Aaron Osborne</name><affiliation wicri:level="1"><nlm:affiliation>Novartis Pharma AG, Basel, Switzerland.</nlm:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Novartis Pharma AG, Basel</wicri:regionArea><wicri:noRegion>Basel</wicri:noRegion></affiliation></author><author><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name><affiliation wicri:level="4"><nlm:affiliation>Centre for Vision Research (Westmead Millennium Institute), University of Sydney, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Centre for Vision Research (Westmead Millennium Institute), University of Sydney, Sydney</wicri:regionArea><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region><settlement type="city">Sydney</settlement></placeName><orgName type="university">Université de Sydney</orgName></affiliation></author></analytic><series><title level="j">Ophthalmology</title><idno type="eISSN">1549-4713</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiogenesis Inhibitors (adverse effects)</term><term>Angiogenesis Inhibitors (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (adverse effects)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Diabetes Mellitus, Type 1 (complications)</term><term>Diabetes Mellitus, Type 2 (complications)</term><term>Diabetic Retinopathy (drug therapy)</term><term>Diabetic Retinopathy (physiopathology)</term><term>Female</term><term>Humans</term><term>Intravitreal Injections</term><term>Laser Coagulation</term><term>Macular Edema (drug therapy)</term><term>Macular Edema (physiopathology)</term><term>Male</term><term>Middle Aged</term><term>Precision Medicine</term><term>Ranibizumab</term><term>Retina (pathology)</term><term>Retreatment</term><term>Sickness Impact Profile</term><term>Surveys and Questionnaires</term><term>Time Factors</term><term>Treatment Outcome</term><term>Visual Acuity (physiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Acuité visuelle (physiologie)</term><term>Adulte d'âge moyen</term><term>Anticorps monoclonaux humanisés (effets indésirables)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Coagulation par laser</term><term>Diabète de type 1 ()</term><term>Diabète de type 2 ()</term><term>Enquêtes et questionnaires</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de l'angiogenèse (effets indésirables)</term><term>Inhibiteurs de l'angiogenèse (usage thérapeutique)</term><term>Injections intravitréennes</term><term>Mâle</term><term>Médecine individualisée</term><term>Oedème maculaire (physiopathologie)</term><term>Oedème maculaire (traitement médicamenteux)</term><term>Profil d'impact de la maladie</term><term>Ranibizumab</term><term>Reprise du traitement</term><term>Résultat thérapeutique</term><term>Rétine (anatomopathologie)</term><term>Rétinopathie diabétique (physiopathologie)</term><term>Rétinopathie diabétique (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Antibodies, Monoclonal, Humanized</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Rétine</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Diabetes Mellitus, Type 1</term><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetic Retinopathy</term><term>Macular Edema</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Inhibiteurs de l'angiogenèse</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Retina</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Acuité visuelle</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Visual Acuity</term></keywords><keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Oedème maculaire</term><term>Rétinopathie diabétique</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Diabetic Retinopathy</term><term>Macular Edema</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Oedème maculaire</term><term>Rétinopathie diabétique</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Inhibiteurs de l'angiogenèse</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Intravitreal Injections</term><term>Laser Coagulation</term><term>Male</term><term>Middle Aged</term><term>Precision Medicine</term><term>Ranibizumab</term><term>Retreatment</term><term>Sickness Impact Profile</term><term>Surveys and Questionnaires</term><term>Time Factors</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Coagulation par laser</term><term>Diabète de type 1</term><term>Diabète de type 2</term><term>Enquêtes et questionnaires</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Injections intravitréennes</term><term>Mâle</term><term>Médecine individualisée</term><term>Profil d'impact de la maladie</term><term>Ranibizumab</term><term>Reprise du traitement</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To evaluate long-term efficacy and safety profiles during 3 years of individualized ranibizumab treatment in patients with visual impairment due to diabetic macular edema (DME).</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Autriche</li><li>France</li><li>Italie</li><li>Pays-Bas</li><li>République populaire de Chine</li><li>Suisse</li></country><region><li>Bade-Wurtemberg</li><li>District de Cologne</li><li>District de Tübingen</li><li>Hollande-Septentrionale</li><li>Nouvelle-Galles du Sud</li><li>Rhénanie-du-Nord-Westphalie</li><li>Vienne (Autriche)</li><li>Île-de-France</li></region><settlement><li>Amsterdam</li><li>Bonn</li><li>Paris</li><li>Sydney</li><li>Ulm</li><li>Vienne (Autriche)</li></settlement><orgName><li>Université de Sydney</li></orgName></list><tree><country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Schmidt Erfurth, Ursula" sort="Schmidt Erfurth, Ursula" uniqKey="Schmidt Erfurth U" first="Ursula" last="Schmidt-Erfurth">Ursula Schmidt-Erfurth</name></region></country><country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Lang, Gabriele E" sort="Lang, Gabriele E" uniqKey="Lang G" first="Gabriele E" last="Lang">Gabriele E. Lang</name></region><name sortKey="Holz, Frank G" sort="Holz, Frank G" uniqKey="Holz F" first="Frank G" last="Holz">Frank G. Holz</name></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Schlingemann, Reinier O" sort="Schlingemann, Reinier O" uniqKey="Schlingemann R" first="Reinier O" last="Schlingemann">Reinier O. Schlingemann</name></region></country><country name="Italie"><noRegion><name sortKey="Lanzetta, Paolo" sort="Lanzetta, Paolo" uniqKey="Lanzetta P" first="Paolo" last="Lanzetta">Paolo Lanzetta</name></noRegion></country><country name="France"><region name="Île-de-France"><name sortKey="Massin, Pascale" sort="Massin, Pascale" uniqKey="Massin P" first="Pascale" last="Massin">Pascale Massin</name></region></country><country name="Suisse"><noRegion><name sortKey="Gerstner, Ortrud" sort="Gerstner, Ortrud" uniqKey="Gerstner O" first="Ortrud" last="Gerstner">Ortrud Gerstner</name></noRegion><name sortKey="Bouazza, Abdelkader Si" sort="Bouazza, Abdelkader Si" uniqKey="Bouazza A" first="Abdelkader Si" last="Bouazza">Abdelkader Si Bouazza</name><name sortKey="Osborne, Aaron" sort="Osborne, Aaron" uniqKey="Osborne A" first="Aaron" last="Osborne">Aaron Osborne</name></country><country name="République populaire de Chine"><noRegion><name sortKey="Shen, Haige" sort="Shen, Haige" uniqKey="Shen H" first="Haige" last="Shen">Haige Shen</name></noRegion></country><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Mitchell, Paul" sort="Mitchell, Paul" uniqKey="Mitchell P" first="Paul" last="Mitchell">Paul Mitchell</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003410 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003410 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24491642
|texte= Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24491642" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |